Nivolumab in NSCLC: Latest evidence and clinical potential

Raghav Sundar, Byoung Chul Cho, Julie R. Brahmer, Ross A. Soo

Research output: Contribution to journalReview articlepeer-review

148 Citations (Scopus)

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Original languageEnglish
Pages (from-to)85-96
Number of pages12
JournalTherapeutic Advances in Medical Oncology
Volume7
Issue number2
DOIs
Publication statusPublished - 2015 Mar

Bibliographical note

Funding Information:
RS, BCC and RAS have no conflicts of interest to declare. JBR has received research funding from Merck and BMS, is a paid consultant for Merck and is a compensated advisory board member for BMS.

Funding Information:
RAS is supported by the National Research Foundation, Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Nivolumab in NSCLC: Latest evidence and clinical potential'. Together they form a unique fingerprint.

Cite this